Daily Cardiology Research Analysis
Three impactful cardiology studies stood out: a phase 3 trial showed the semaglutide/cagrilintide combination (CagriSema) substantially lowers blood pressure in adults with overweight/obesity; a genome-wide gene-by-sleep interaction analysis (n=732,564) identified novel lipid loci, revealing how sleep duration modifies genetic effects on lipids; and mechanistic work uncovered Ets1-regulated endothelial signals driving compact myocardial growth, illuminating therapeutic targets for ventricular no
Summary
Three impactful cardiology studies stood out: a phase 3 trial showed the semaglutide/cagrilintide combination (CagriSema) substantially lowers blood pressure in adults with overweight/obesity; a genome-wide gene-by-sleep interaction analysis (n=732,564) identified novel lipid loci, revealing how sleep duration modifies genetic effects on lipids; and mechanistic work uncovered Ets1-regulated endothelial signals driving compact myocardial growth, illuminating therapeutic targets for ventricular non-compaction.
Research Themes
- Metabolic therapies for cardiovascular risk modification
- Gene–environment interactions in cardiometabolic traits
- Endothelial–myocardial signaling in developmental cardiomyopathy
Selected Articles
1. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
In REDEFINE 1, 68 weeks of CagriSema yielded a −10.9/−5.4 mmHg reduction in systolic/diastolic BP versus placebo, doubled the proportion achieving BP targets, and allowed de-escalation of antihypertensives in ~40% of users. Benefits were observed across subgroups, including resistant hypertension.
Impact: Large, randomized phase 3 data show a weight-loss agent combination yields clinically meaningful BP reductions, potentially reframing hypertension management in obesity.
Clinical Implications: For adults with obesity and elevated BP, CagriSema may provide dual benefits (weight loss and BP lowering), enabling BP target attainment and medication de-escalation. Clinicians should monitor for hypotension and individualize antihypertensive adjustments.
Key Findings
- BP change at 68 weeks: −10.9/−5.4 mmHg (systolic/diastolic) with CagriSema vs −2.8/−1.7 mmHg with placebo.
- BP target attainment: 63.0% with CagriSema vs 32.0% with placebo.
- Among resistant hypertension at baseline (n=167), BP target attainment 42.0% vs 29.3% (CagriSema vs placebo).
- 39.6% of antihypertensive users on CagriSema decreased or stopped therapy vs 18.8% with placebo.
Methodological Strengths
- Phase 3a randomized, controlled trial with large sample (n=3417) and pre-registration (NCT05567796).
- Clinically relevant secondary endpoints with subgroup analyses, including resistant hypertension.
Limitations
- Diabetes excluded; generalizability to patients with diabetes is uncertain.
- Cardiovascular outcomes were not assessed; BP was a secondary endpoint in a weight-loss trial.
- Details on antihypertensive titration protocols are limited.
Future Directions: Evaluate hard cardiovascular outcomes and renal endpoints, assess efficacy in patients with diabetes, and define standardized antihypertensive de-escalation pathways with CagriSema.
BACKGROUND: Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo. METHODS: The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m RESULTS: Overall, 3417 participants underwent randomization; CagriSema: n=2108, semaglutide: n=302, cagrilintide: n=302, and placebo: n=705. Changes from baseline to week 68 in blood pressure (BP) were greater with CagriSema versus placebo (systolic BP: -10.9 versus -2.8 mm Hg; diastolic BP: -5.4 versus -1.7 mm Hg, respectively). The proportion of participants reaching BP targets at week 68 was 63.0% and 32.0% for CagriSema and placebo, respectively. The proportion of participants with resistant hypertension at baseline (n=167) that reached BP targets at week 68 was 42.0% and 29.3% for CagriSema and placebo, respectively (odds ratio, 1.7 [95% CI, 0.7-4.4]). Among participants who used antihypertensive medication during the study, 39.6% in the CagriSema group decreased or stopped treatment from week 0 to week 68 versus 18.8% with placebo. CONCLUSIONS: CagriSema presents clinically relevant reductions in BP across a wide range of participant subgroups, including those with resistant hypertension. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05567796.
2. Genome-wide gene-sleep interaction study identifies novel lipid loci in 732,564 participants.
Across 55 cohorts (n=732,564), short or long sleep modified genetic effects on HDL-C, LDL-C, and TG, yielding 17 significant loci in interaction or joint tests. Pathway signals implicated vitamin D receptor-related biology in sleep-associated lipid regulation.
Impact: This is one of the largest gene–environment interaction studies in cardiometabolic traits, revealing how sleep duration alters genetic influences on lipids and nominating druggable pathways.
Clinical Implications: While not immediately actionable, results support incorporating sleep assessment in cardiometabolic risk models and motivate trials testing pathway-targeted interventions (e.g., vitamin D signaling) in sleep-disturbed populations.
Key Findings
- Meta-analysis across 55 cohorts (n=732,564) identified 17 loci where sleep duration modified genetic effects on lipids (9 short-sleep, 8 long-sleep).
- Interaction testing discovered 10 novel loci; joint tests integrating main and interaction effects further expanded discovery.
- Pathway signals implicated vitamin D receptor biology in sleep-associated lipid regulation.
Methodological Strengths
- Exceptionally large sample size and multi-cohort meta-analysis design.
- Formal interaction and joint testing frameworks increase discovery power for gene–environment effects.
Limitations
- Predominantly European ancestry (87%), limiting generalizability.
- Sleep duration definitions rely on cohort-specific standardized extremes; measurement heterogeneity likely.
- Observational design precludes causal inference; functional validation is pending.
Future Directions: Replicate in non-European ancestries, integrate objective sleep measures (actigraphy), and perform functional studies to validate candidate genes and pathways (e.g., vitamin D receptor signaling).
BACKGROUND AND AIMS: Deviations from the population mean in sleep duration have been associated with increased risk for developing dyslipidemia and atherosclerotic cardiovascular disease, but the mechanism of effect is poorly characterized. We performed large-scale genome-wide gene-sleep interaction analyses of lipid levels to identify genetic variants underpinning the biomolecular pathways of sleep-associated lipid disturbances and to suggest possible druggable targets. METHODS: We collected data from 55 cohorts with a combined sample size of 732,564 participants (87 % European ancestry) with data on lipid traits (high-density lipoprotein [HDL-c] and low-density lipoprotein [LDL-c] cholesterol and triglycerides [TG]). Short (STST) and long (LTST) total sleep time were defined by the extreme 20 % of the age- and sex-standardized values within each cohort. Based on cohort-level summary statistics data, we performed meta-analyses for one-degree of freedom tests of interaction and two-degree of freedom joint tests of the SNP-main and -interaction effect on lipid levels. RESULTS: The one-degree of freedom variant-sleep interaction test identified 10 novel loci (P CONCLUSIONS: Collectively, the 17 (9 with short and 8 with long sleep) loci provided evidence into the biomolecular mechanisms underlying sleep-associated lipid changes, including potential involvement of the vitamin D receptor pathway. Collectively, these findings may contribute developing novel interventions for treating dyslipidemia in people with sleep disturbances.
3. Ets1-regulated endothelial-secreted factors promote compact myocardial growth and contribute to the pathogenesis of ventricular non-compaction.
Endothelial Ets1 orchestrates compact myocardial growth via Notch1 signaling and secretion of ECM factors. Conditional Ets1 deletion in endocardial or coronary endothelium impairs proliferation; exogenous Hmcn1, Slit2, Col18a1, or Notch1 effector Nrg1 restore growth, nominating targets for ventricular non-compaction.
Impact: Provides mechanistic, targetable pathways linking endothelial biology to compact myocardium development and ventricular non-compaction, with rescue experiments supporting translational potential.
Clinical Implications: Although preclinical, findings support exploring ECM protein delivery or Notch1/Nrg1 pathway modulation as therapeutic strategies for ventricular non-compaction.
Key Findings
- Single-cell RNA-seq revealed aberrant endothelial and cardiomyocyte states in non-compacted ventricles.
- Ets1 deletion in endocardium suppressed Notch1 signaling via Dlk1 upregulation and Dll4 downregulation.
- Ets1 deletion in coronary endothelium reduced Hmcn1, Slit2, and Col18a1, ECM components that promote proliferation.
- Exogenous ECM proteins or Notch1 effector Nrg1 restored compact myocardial proliferation.
Methodological Strengths
- Use of conditional endothelial-specific knockouts dissecting compartmental roles (endocardium vs coronary endothelium).
- Orthogonal validation with single-cell transcriptomics and functional rescue using ECM proteins/Nrg1.
Limitations
- Preclinical models; human validation is lacking.
- Long-term safety and delivery strategies for ECM or Nrg1 therapies remain untested.
Future Directions: Validate Ets1-dependent targets in human ventricular non-compaction tissues; develop delivery systems for ECM/Nrg1; assess efficacy and safety in large-animal models.
AIMS: Thinning of the compact myocardium is a major contributor to adverse outcomes in ventricular non-compaction, the third most common form of cardiomyopathy. Endothelial-specific deletion of Ets1, a gene associated with Jacobsen syndrome, causes ventricular non-compaction with reduced compact myocardium. However, the mechanisms by which pathological cardiac endothelium impairs compact myocardium growth remain poorly understood. METHODS AND RESULTS: To uncover the mechanisms underlying compact myocardium thinning and identify therapeutic endothelial-secreted factors, we performed single-cell RNA sequencing. Aberrant cardiomyocyte and endothelial cell states were observed in non-compacted ventricles. Conditional deletion of Ets1 in either the endocardium or coronary endothelium impaired compact myocardial growth. In endocardium, Ets1 deficiency suppressed Notch1 signaling by upregulating Dlk1 and downregulating Dll4, both direct Ets1 targets. In coronary endothelium, Ets1 deficiency reduced the expression of its direct targets Hmcn1, Slit2, and Col18a1, three extracellular matrix (ECM) components that promote compact myocardial proliferation. Notably, treatment with these ECM proteins or the Notch1 effector Nrg1 restored the impaired compact myocardial proliferation. CONCLUSIONS: These findings highlight Ets1-regulated endothelial-secreted factors as essential for compact myocardium development and suggest novel therapeutic targets for ventricular non-compaction.